View Archive

Credit Designation

Physicians' Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by educational grants from Agios Pharmaceuticals, Inc., and Incyte Corporation.

Not an official event of the 2021 Gastrointestinal Cancers Symposium. Not sponsored, endorsed, or accredited by any of the cosponsoring organizations of the 2021 Gastrointestinal Cancers Symposium.

Medical Crossfire®: Navigating the Advent of Novel Targeted and Immunotherapeutic Approaches in Cholangiocarcinoma

Medical Crossfire®: Navigating the Advent of Novel Targeted and Immunotherapeutic Approaches in Cholangiocarcinoma

Saturday, January 16, 2021

Live, Interactive Virtual Webcast!

7:00 PM – 9:00 PM EST


The past year brought new advances for the treatment of cholangiocarcinoma, which is a rare biliary tract malignancy and an aggressive disease. While surgical and locoregional therapies for early-stage disease can yield significant survival improvements, patients with unresectable advanced cholangiocarcinoma have a poor prognosis, with 5-year overall survival rates between 5% and 10%. The use of systemic chemotherapy, biliary stenting, or locoregional treatments have had limited benefit; but novel targets based on understanding of tumor biology and pathophysiology have already shifted treatment paradigms for patients with biomarkers, such as mutated isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2), fibroblast growth factor receptor (FGFR), microsatellite instability-high (MSI-H), and other mutated genes.

The Medical Crossfire®, one of PER’s signature educational formats, is a live webcast program in which a panel of distinguished experts engage in spirted discussions and debates on novel approaches in cholangiocarcinoma. In this activity, 3 key thought leaders explore the latest data regarding unmet needs, advances in pathophysiology, and emerging therapeutic strategies for the management of cholangiocarcinoma across lines of care. This dynamic discussion will help place new developments into clinical context to help you optimize care for your patients with cholangiocarcinoma.

Benefits of Attending

  • Learn about novel targets for the treatment of cholangiocarcinoma guided by advancements in understanding pathophysiology and tumor biology
  • Obtain expert recommendations for best practices in diagnosing, managing, and treating patients with cholangiocarcinoma
  • Gain insights into how the experts handle challenging, real-world clinical cases in cholangiocarcinoma

Acknowledgment of Commercial Support

This activity is supported by educational grants from Agios Pharmaceuticals, Inc., and Incyte Corporation.

Target Audience

This educational program is directed toward all attendees of the 2021 Gastrointestinal Cancers Symposium, including a global audience of medical oncologists, surgical oncologists, radiation oncologists, hepatologists, pathologists, and gastroenterologists interested in the treatment of cholangiocarcinoma. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with cholangiocarcinoma are also invited to participate.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Explain the biologic rationale that has informed recent clinical development of targeted and immunotherapeutic approaches for cholangiocarcinoma
  • Integrate key genomic and molecular testing strategies that allow for cholangiocarcinoma tumor characterization and inform decision-making for patients with these tumors
  • Apply practice-changing evidence on novel immunotherapies and targeted therapies to clinical scenarios encountered in cholangiocarcinoma management
  • Promulgate multidisciplinary approaches to identify and mitigate the impact of treatment-related toxicities in the care of patients with cholangiocarcinoma

Program Chair

Andrew Zhu, MD, PhD
Andrew X. Zhu, MD, PhD
Director Emeritus, Liver Cancer Research
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School
Boston, MA
Director, Jiahui International Cancer Center
Shanghai, China


2 Ways to Register
  1. Online: click here.
  2. Phone: Please call (888) 949-0045 or (609) 378-3701.
Physicians' Education Resource®
2 Clarke Drive
Suite 110
Cranbury, NJ 08512
Registration Fee - Free

For registration assistance, please email info@gotoper.com, or call (888) 949-0045 or (609) 378-3701.

Physicians' Education Resource®, LLC reserves the exclusive rights to all recordings or reproductions of the conference and supporting materials. Unauthorized recording, by any means, is expressly prohibited.  This includes, but is not limited to, recording of presentations or reproductions of supporting audio/visual materials, exhibits, and other supporting Continuing Education materials.

Meeting information is accurate at the time of posting.


You must be logged in to PER to register for this meeting

Or Register for PER now

*Required Fields

Login Information

Registration Information

Professional Information


Calendar of Events
Filter By